SAN FRANCISCO—The ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted therapies to treat renal cancer, according to Dr Tom Powles MBBS, MRCP, MD speaking at the ASCO GU Cancers Symposium here. Dr Tomasz Beer, MD FACP from Oregon Health & Science University in Portland acknowledged that heterogeneity was also a barrier to prostate cancer treatment but he felt it would be overcome in this and other genitourinary cancers by using combination targeted therapies just as HIV-AIDS was being beaten by multi-drug approaches.
Dr. Tom Powles MBBS, MRCP, MD
Barts Cancer Institute, London, UK SOURCE:
General Session: Clinical and genetic heterogeneity in renal cell carcinoma